Neprilysin is an enzyme that breaks down peptides, including natriuretic hormones and amyloid-beta, regulating blood pressure, fluid balance, and neurochemical activity.
Neprilysin, also called neutral endopeptidase (NEP), cleaves peptide bonds in small proteins. It targets natriuretic peptides (like ANP and BNP), which lower blood pressure by promoting vasodilation and reducing sodium retention. The enzyme also degrades amyloid-beta, a protein linked to Alzheimer's disease.
| Peptide Substrate | Function |
|---|---|
| Atrial Natriuretic Peptide (ANP) | Reduces blood pressure and volume |
| Brain Natriuretic Peptide (BNP) | Lowers stress on heart tissue |
| Amyloid-Beta | Prevents plaque buildup in brain |
Neprilysin is active in the kidneys, lungs, and brain. In medicine, it's a target for treating heart failure and hypertension. Drugs like sacubitril inhibit neprilysin to prolong natriuretic peptide effects, improving cardiac function. Research also explores its role in neurodegenerative diseases.
Some assume neprilysin only affects the cardiovascular system. However, it also influences neuroprotection by breaking down amyloid-beta. Unlike ACE inhibitors, which target angiotensin, neprilysin inhibitors work on a different pathway.
In 2015, the FDA approved Entresto (sacubitril/valsartan) for heart failure. Sacubitril inhibits neprilysin, increasing natriuretic peptide levels. This reduces blood pressure and heart strain, improving survival rates. Clinical trials showed a 20% lower risk of cardiovascular death compared to standard treatments.
Neprilysin's role extends beyond heart health. Research from the Journal of Neurochemistry highlights its potential in slowing Alzheimer's progression by degrading amyloid-beta. Understanding this enzyme offers insights into treating chronic diseases.